Item 2.02 Results of Operations and Financial Condition

On May 7, 2020, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2020 second quarter financial results for the period ended March 31, 2020. A copy of the press release is furnished herewith as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits




Exhibit No.   Description



99.1            Press Release, dated May 7, 2020.




104          Cover Page Interactive File (the cover page tags are embedded within
             the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses